LONDON (ShareCast) - (Sharecast News) - Software group Cambridge Cognition said on Thursday that it has secured a £1.0m contract to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical trial.
Cambridge Cognition said the initial contract, which was with "a major pharmaceutical company", will start in 2025 and run through to 2031.

The AIM-listed firm noted that it has previously provided services to this customer, with the new contract representing repeat business with the "global company".

Cambridge Cognition added that it was selected to support the study due to its "scientifically validated, proprietary cognitive assessments" and its "proven ability to deliver digital cognitive testing solutions on a global scale".

Supported by an experienced clinical project management team, Cambridge Cognition will deploy its CANTAB asset will be deployed in 16 countries and 23 languages across 245 trial sites.

As of 1150 BST, Cambridge Cognition shares were up 0.20% at 33.06p.









Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE